Corbus Pharmaceuticals Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating immune modulators designed to combat immuno-oncology and various fibrotic conditions. Its pipeline includes lenabasum, an orally administered small molecule. This compound selectively activates cannabinoid receptor type 2 (CB2) and is currently undergoing Phase II clinical trials for the treatment of systemic lupus erythematosus. The company is also advancing CRB-601, an anti-integrin monoclonal antibody (mAb) engineered to inhibit the activation of transforming growth factor ß (TGFß), which it is developing for both cancer and fibrotic indications. Another key asset is CRB-602, an anti-avß6/avß8 mAb designed to block TGFß activation, specifically for addressing fibrotic diseases. Beyond these, Corbus is pursuing a cannabinoid receptor type 1 inverse agonist program. This broad-spectrum initiative targets several conditions, including metabolic disorders such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; various fibrotic diseases, like lung, cardiac, renal, and liver fibrosis; and other ailments, including ascites, cognitive impairments, Prader-Willi syndrome, and smoking cessation. In terms of collaborations, Corbus has a licensing agreement with Jenrin Discovery, LLC. This partnership grants them rights to develop and commercialize products, encompassing Jenrin's extensive library of approximately 600 compounds, alongside numerous issued and pending patent applications. Established in 2009, the company's headquarters are located in Norwood, Massachusetts.
